Efficacy and safety of transjugular intrahepatic portosystemic shunt (TIPSS) in 40 patients with hepatocellular carcinoma

Alimentary Pharmacology and Therapeutics

Volumn 41, Issue 1, 2015, Pages 126-136

  Bettinger, D ^a   Knuppel E ^a   Euringer, W ^a   Spangenberg, H C ^a   Rossle M ^a,b   Thimme, R ^a   Schultheiss M ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b PraxisZentrum für Gastroenterologie und Endokrinologie   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; ASCITES; BARE METAL STENT; BLEEDING; CANCER MORTALITY; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; COVERED STENT; FEMALE; FOLLOW UP; HEMORRHAGIC SHOCK; HEPATIC ENCEPHALOPATHY; HUMAN; INTENSIVE CARE; LIVER CELL CARCINOMA; LIVER FUNCTION; LUNG METASTASIS; MALE; MULTIPLE ORGAN FAILURE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PORTAL VEIN THROMBOSIS; PORTOSYTEMIC GRADIENT; PRESSURE GRADIENT; SHUNT THROMBOSIS; SURVIVAL TIME; TIPS ENDOPROSTHESIS; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; TUMOR GROWTH; TUMOR INVASION; VARICEAL BLEEDING; VASCULAR STENT; ADVERSE EFFECTS; COMPLICATION; ESOPHAGEAL AND GASTRIC VARICES; GASTROINTESTINAL HEMORRHAGE; HYPERTENSION, PORTAL; LIVER TUMOR; MIDDLE AGED; MORTALITY; PROCEDURES; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ASCITES; CARCINOMA, HEPATOCELLULAR; ESOPHAGEAL AND GASTRIC VARICES; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; HYPERTENSION, PORTAL; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84915749012     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12994     Document Type: Article

References (60)

1. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010;53:397-417.
2. Cardenas A, Gines P. Management of patients with cirrhosis awaiting liver transplantation. Gut 2011; 60: 412-21.
3. Cabrera R, Nelson DR. Review article: the management of hepatocellular carcinoma. Aliment Pharmacol Ther 2010; 31: 461-76.
4. Ruzzenente A, Valdegamberi A, Campagnaro T, et al. Hepatocellular carcinoma in cirrhotic patients with portal hypertension: is liver resection always contraindicated? World J Gastroenterol 2011; 17: 5083-8.
5. Santambrogio R, Kluger MD, Costa M, et al. Hepatic resection for hepatocellular carcinoma in patients with Child-Pugh 's A cirrhosis: is clinical evidence of portal hypertension a contraindication? HPB 2013; 15: 78-84.
6. Kanwal F, Befeler A, Chari RS, et al. Potentially curative treatment in patients with hepatocellular cancer-results from the liver cancer research network. Aliment Pharmacol Ther 2012; 36: 257-65.
7. European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-43.
8. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.
9. Villanueva C, Piqueras M, Aracil C, et al. A randomized controlled trial comparing ligation and sclerotherapy as emergency endoscopic treatment added to somatostatin in acute variceal bleeding. J Hepatol 2006; 45 : 560-7.
10. McCormick PA, O'Keefe C. Improving prognosis following a first variceal haemorrhage over four decades. Gut 2001; 49: 682-5.
11. Singal AK, Jampana SC, Singal V, Kuo YF. Hepatocellular carcinoma predicts in-hospital mortality from acute variceal hemorrhage among patients with cirrhosis. J Clin Gastroenterol 2012; 46: 613-9.
12. Fidelman N, Kwan SW, LaBerge JM, Gordon RL, Ring EJ, Kerlan RK Jr. The transjugular intrahepatic portosystemic shunt: an update. AJR Am J Roentgenol 2012; 199: 746-55.
13. Rossle M. TIPS: 25 years later. J Hepatol 2013; 25: 00430-3.
14. Cello JP. Endoscopic management of esophageal variceal hemorrhage: injection, banding, glue, octreotide, or a combination? Semin Gastrointest Dis 1997; 8: 179-87.
15. Rossle M, Ochs A, Gulberg V, et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 2000; 342: 1701-7.
16. Rossle M, Deibert P, Haag K, et al. Randomised trial of transjugular-intrahepatic-portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. Lancet 1997; 349: 1043-9.
17. Gordon FD, Anastopoulos HT, Crenshaw W, et al. The successful treatment of symptomatic, refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt. Hepatology 1997; 25: 1366-9.
18. Siegerstetter V, Deibert P, Ochs A, Olschewski M, Blum HE, Rossle M. Treatment of refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt: long-term results in 40 patients. Eur J Gastroenterol Hepatol 2001; 13: 529-34.
19. Garcia-Pagan JC, Caca K, Bureau C, et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med 2010; 362: 2370-9.
20. Kuiper JJ, de Man RA, van Buuren HR. Review article: management of ascites and associated complications in patients with cirrhosis. Aliment Pharmacol Ther 2007; 2: 183-93.
21. Kochar N, Tripathi D, McAvoy NC, Ireland H, Redhead DN, Hayes PC. Bleeding ectopic varices in cirrhosis: the role of transjugular intrahepatic portosystemic stent shunts. Aliment Pharmacol Ther 2008; 28: 294-303.
22. Attwell A, Ludkowski M, Nash R, Kugelmas M. Treatment of Budd-Chiari syndrome in a liver transplant unit, the role of transjugular intrahepatic portosystemic shunt and liver transplantation. Aliment Pharmacol Ther 2004; 20: 867-73.
23. Cardenas A, Kelleher T, Chopra S. Review article: hepatic hydrothorax. Aliment Pharmacol Ther 2004; 20: 271-9.
24. Tripathi D, Macnicholas R, Kothari C, et al. Good clinical outcomes following transjugular intrahepatic portosystemic stent-shunts in Budd-Chiari syndrome. Aliment Pharmacol Ther 2014; 39: 864-72.
25. Haskal ZJ, Martin L, Cardella JF, et al. Quality improvement guidelines for transjugular intrahepatic portosystemic shunts. SCVIR Standards of Practice Committee. J Vasc Interv Radiol 2001; 12: 131-6.
26. Wallace MJ, Madoff DC. Transjugular intrahepatic portosystemic shunts in patients with hepatic malignancy. Semin Intervent Radiol 2005; 22: 309-15.
27. Wallace MJ, Madoff DC, Ahrar K, Warneke CL. Transjugular intrahepatic portosystemic shunts: experience in the oncology setting. Cancer 2004; 101: 337-45.
28. Liu L, Zhao Y, Qi X, et al. Transjugular intrahepatic portosystemic shunt for symptomatic portal hypertension in hepatocellular carcinoma with portal vein tumor thrombosis. Hepatol Res 2013; 17: 12162.
29. Couinaud C. Liver anatomy: portal (and suprahepatic) or biliary segmentation. Dig Surg 1999; 16: 459-67.
30. de Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2005; 43: 167-76.
31. Moore KP, Wong F, Gines P, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 2003; 38: 258-66.
32. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy - definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002; 35: 716-21.
33. Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698-711.
34. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60.
35. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-9.
36. Rossle M, Grandt D. TIPS: an update. Best Pract Res Clin Gastroenterol 2004; 18: 99-123.
37. Rossle M, Siegerstetter V, Huber M, Ochs A. The first decade of the transjugular intrahepatic portosystemic shunt (TIPS): state of the art. Liver 1998; 18: 73-89.
38. Rossle M, Haag K, Ochs A, et al. The transjugular intrahepatic portosystemic stent-shunt procedure for variceal bleeding. N Engl J Med 1994; 330: 165-71.
39. Radosevich PM, Ring EJ, LaBerge JM, et al. Transjugular intrahepatic portosystemic shunts in patients with portal vein occlusion. Radiology 1993; 186: 523-7.
40. Walser EM, NcNees SW, DeLa Pena O, et al. Portal venous thrombosis: percutaneous therapy and outcome. J Vasc Interv Radiol 1998; 1: 119-27.
41. Senzolo M, Tibbals J, Cholongitas E, Triantos CK, Burroughs AK, Patch D. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with and without cavernous transformation. Aliment Pharmacol Ther 2006; 23: 767-75.
42. Liu L, Zhao Y, Qi X, et al. Transjugular Intrahepatic Portosystemic Shunt for Symptomatic Portal Hypertension in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Hepatol Res 2014; 44: 621-30.
43. Liu CL, Fan ST, Lo CM, et al. Management of spontaneous rupture of hepatocellular carcinoma: single-center experience. J Clin Oncol 2001; 19: 3725-32.
44. Wallace M, Swaim M. Transjugular intrahepatic portosystemic shunts through hepatic neoplasms. J Vasc Interv Radiol 2003; 14: 501-7.
45. Lee YH, Hsu CY, Hsia CY, et al. A prognostic model for patients with hepatocellular carcinoma within the Milan criteria undergoing nontransplant therapies, based on 1106 patients. Aliment Pharmacol Ther 2012; 36: 551-9.
46. Saxon RS, Ross PL, Mendel-Hartvig J, et al. Transjugular intrahepatic portosystemic shunt patency and the importance of stenosis location in the development of recurrent symptoms. Radiology 1998; 207: 683-93.
47. Saxon RR, Mendel-Hartvig J, Corless CL, et al. Bile duct injury as a major cause of stenosis and occlusion in transjugular intrahepatic portosystemic shunts: comparative histopathologic analysis in humans and swine. J Vasc Interv Radiol 1996; 7: 487-97.
48. Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol 1954; 30: 969-77.
49. Kudo M, Hatanaka K, Inoue T, Maekawa K. Depiction of portal supply in early hepatocellular carcinoma and dysplastic nodule: value of pure arterial ultrasound imaging in hepatocellular carcinoma. Oncology 2010; 1: 60-7.
50. Kang JW, Kim JH, Ko GY, Gwon DI, Yoon HK, Sung KB. Transarterial chemoembolization for hepatocellular carcinoma after transjugular intrahepatic portosystemic shunt. Acta Radiol 2012; 53: 545-50.
51. Kuo YC, Kohi MP, Naeger DM, et al. Efficacy of TACE in TIPS patients: comparison of treatment response to chemoembolization for hepatocellular carcinoma in patients with and without a transjugular intrahepatic portosystemic shunt. Cardiovasc Intervent Radiol 2013; 36: 1336-43.
52. Itkin M, Trerotola SO, Stavropoulos SW, et al. Portal flow and arterioportal shunting after transjugular intrahepatic portosystemic shunt creation. J Vasc Interv Radiol 2006; 17: 55-62.
53. Mingoli A, Modini C, Salvatori F, et al. Emergency transjugular intrahepatic portosystemic shunt in patients with active variceal bleeding and hepatocarcinoma. Ital J Gastroenterol 1995; 27: 309-12.
54. Sakaguchi H, Uchida H, Maeda M, et al. Combined transjugular intrahepatic portosystemic shunt and segmental Lipiodol hepatic artery embolization for the treatment of esophagogastric varices and hepatocellular carcinoma in patients with cirrhosis: preliminary report. Cardiovasc Intervent Radiol 1995; 18: 9-15.
55. Nicolini A, Saccheri S, Lovaria A, et al. Prevention of variceal rebleeding and treatment of liver carcinoma by consecutive transjugular intrahepatic portosystemic shunt and hepatic artery chemoembolization. Ital J Gastroenterol 1996; 28: 269-71.
56. Serafini FM, Zwiebel B, Black TJ, Carey LC, Rosemurgy AS 2nd. Transjugular intrahepatic portasystemic stent shunt in the treatment of variceal bleeding in hepatocellular cancer. Dig Dis Sci 1997; 42: 59-65.
57. Tazawa J, Sakai Y, Yamane M, et al. Long-term observation after transjugular intrahepatic portosystemic stent-shunt in two patients with hepatocellular carcinoma. J Clin Gastroenterol 2000; 31: 262-7.
58. Hur J, Lee KH, Lee JH, Yu JS, Won JY, Lee DY. Stent-graft for TIPS in a hepatocellular carcinoma patient with main portal vein invasion. AJR Am J Roentgenol 2004; 182: 1301-4.
59. Jiang ZB, Shan H, Shen XY, et al. Transjugular intrahepatic portosystemic shunt for palliative treatment of portal hypertension secondary to portal vein tumor thrombosis. World J Gastroenterol 2004; 10: 1881-4.
60. Bezzi M, Broglia L, Lemos AA, Rossi P. Transjugular intrahepatic portosystemic shunt in portal vein thrombosis: role of the right gastric vein with anomalous insertion. Cardiovasc Intervent Radiol 1995; 18: 102-5.